SEC Settles Insider Trading Suit Over Pharma Deal

Law360, New York (September 2, 2010, 6:41 PM EDT) -- A former hedge fund manager and an executive with a New Jersey-based pharmaceutical company, both facing insider trading charges tied to AstraZeneca’s acquisition of MedImmune Inc. in 2007, have agreed to settle a U.S. Securities and Exchange Commission case against them.

Stephen R. Goldfield, the hedge fund manager, was able to rack up nearly $14 million in illegal profits, thanks to nonpublic information funneled to him by longtime friend and business executive James W. Self Jr., the SEC alleged in a complaint filed Wednesday in the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.